| Sanofi, Novartis, Astrazeneca get poor results from trial tests on key drugs - Washington Post |
|
|
Washington Post In Basel, Switzerland, Novartis said it was terminating a trial of its high blood pressure treatment Rasilez in high-risk patients with diabetes and renal impairment. The drugmaker said in a statement that it terminated the study on the recommendation ... Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in |